A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs GO 203 2c (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- 09 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017.
- 27 Jul 2016 Planned initiation date changed from 1 Feb 2016 to 1 Dec 2016.